MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics

MICA：英格兰西北部 MRC 临床药理学和治疗学奖学金计划

• 批准号: MR/N025989/1
• 负责人: Munir Pirmohamed
• 金额: $ 229.32万
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FN025989%2F1
• 关键词: MICA; North; West; England; MRC

Clinical pharmacologists are physicians and scientists whose focus is developing and understanding existing and new drug therapies; they work in a variety of settings in academia, the NHS, industry and government. In the clinical setting, they work directly with patients, participate in trials, and investigate how patients respond to drugs, including why certain patients develop side effects to drugs. The total number of academic clinical pharmacologists trained in the UK is small, and there is an imperative to continue to train more clinical pharmacologists and other specialists with expertise in clinical pharmacology who can work between academia, healthcare and industry. In 2010, the Government recognised that the provision of high quality-care and better interaction with Industry requires clinicians to be familiar with the relevant practices in clinical pharmacology. The universities of Liverpool and Manchester, in collaboration with industry partners, were awarded funding from the MRC to address this unmet need in clinical pharmacology: The North West England MRC Clinical Research Training Fellowship Programme in Clinical Pharmacology and Therapeutics. This programme has allowed 13 clinical fellows (high flying trainee doctors), rigorously selected from across all medical specialties e.g. dermatology, rheumatology, paediatrics etc., to study for PhDs on a variety of clinical pharmacology related research topics such as drug safety and stratified medicine - matching the right drug to the right patient. In addition to their research work the fellows received without walls training with industry and modular training in key aspects of clinical pharmacology. The programme has been a tremendous success with 56 scientific journal publications, 21 conference presentations, 13 prizes and interactions with 61 NHS Trusts. All fellows will also get a PhD.We now wish to renew the scheme with the MRC and with 4 industry partners - Lilly, Novartis, Roche and UCB Pharma, to appoint 13 more fellows. The previous successful format and structure will be retained as will joint leadership from the two universities. Refinements to the programme include: increasing the number of industry partners thereby allowing us to cover more therapeutic areas including cancer; lengthening of the recruitment process to give potential fellows, their supervisors and industry representatives more time to develop research projects with strong alignment; identification of a lead industry partner for each fellow from the beginning of the programme to develop a partnership from the outset; ensuring, where possible, that fellows can spend up to one year with the industry partner at their site(s) performing different aspects of their project. These changes will enhance fellows' training with industry, and also increase the input provided by industry in individual projects. There will be very strong patient and public engagement (as in the current scheme) with involvement of patients in the planning of research proposals, a number of public lectures and involvement of fellows at events such as the Manchester Science Spectacular. The Fellowship Programme will go some way to producing academics with expertise in clinical pharmacology and helping to optimise the safe, targeted prescribing of existing drugs and the development of new therapies for human disease.

临床药理学家是医生和科学家，他们的重点是开发和理解现有的和新的药物疗法;他们在学术界，NHS，工业和政府的各种环境中工作。在临床环境中，他们直接与患者合作，参与试验，并调查患者对药物的反应，包括为什么某些患者对药物产生副作用。在英国接受培训的学术临床药理学家的总数很少，必须继续培养更多的临床药理学家和其他具有临床药理学专业知识的专家，他们可以在学术界，医疗保健和工业界之间工作。2010年，政府认识到，提供高质量的护理和与行业更好的互动需要临床医生熟悉临床药理学的相关实践。利物浦和曼彻斯特大学与行业合作伙伴合作，获得了MRC的资助，以解决临床药理学中未满足的需求：英格兰西北部MRC临床药理学和治疗学临床研究培训奖学金计划。该方案使13名临床研究员（雄心勃勃的实习医生）从所有医学专业（如皮肤科、风湿科、儿科等）中严格挑选出来，攻读各种临床药理学相关研究课题的博士学位，如药物安全性和分层医学-将正确的药物与正确的患者相匹配。除了他们的研究工作外，研究员还接受了临床药理学关键方面的无围墙培训和行业培训。该计划取得了巨大的成功，有56份科学期刊出版物，21次会议演讲，13个奖项以及与61个NHS信托基金的互动。所有研究员也将获得博士学位。我们现在希望与MRC和4个行业合作伙伴-礼来，诺华，罗氏和UCB制药，任命13个研究员更新计划。以前成功的形式和结构将保留，两所大学的联合领导也将保留。该计划的改进包括：增加行业合作伙伴的数量，从而使我们能够覆盖更多的治疗领域，包括癌症;延长招聘过程，使潜在的研究员，他们的主管和行业代表有更多的时间来开发具有强有力的协调性的研究项目;从计划一开始就为每个研究员确定一个主要的行业合作伙伴，从一开始就建立伙伴关系;在可能的情况下，确保研究员能够在其所在地与行业合作伙伴共同开展项目的不同方面，时间最长可达一年。这些变化将加强研究员对工业界的培训，并增加工业界对个别项目的投入。将有非常强的病人和公众参与（如在目前的计划）与病人参与规划的研究建议，一些公开讲座和研究员参与活动，如曼彻斯特科学壮观。该奖学金计划将在一定程度上培养具有临床药理学专业知识的学者，并帮助优化现有药物的安全，有针对性的处方和开发人类疾病的新疗法。

项目成果

Update on risankizumab for the treatment of moderate to severe psoriasis.

risankizumab 用于治疗中度至重度银屑病的最新进展。

• DOI: 10.1080/14712598.2020.1822813
• 发表时间: 2020
• 期刊: Expert opinion on biological therapy
• 影响因子: 4.6
• 作者: Al-Janabi A

The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.

免疫调节剂对免疫介导的炎症性疾病患者接种 BNT162b2 和 AZD1222 疫苗后血清转化的影响：一项前瞻性队列研究。

• DOI: 10.1093/bjd/ljac109
• 发表时间: 2023
• 期刊: The British journal of dermatology
• 作者: Al-Janabi A

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.

• DOI: 10.1001/jamadermatol.2023.4846
• 发表时间: 2024-01-01
• 期刊: JAMA DERMATOLOGY
• 影响因子: 10.9
• 作者: Al-Janabi, Ali;Alabas, Oras A.;Yiu, Zenas Z. N.;Foulkes, Amy C.;Eyre, Steve;Khan, Adnan R.;Reynolds, Nick J.;Smith, Catherine H.;Griffiths, Christopher E. M.;Warren, Richard B.
• 通讯作者: Warren, Richard B.

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management.

• DOI: 10.2147/ptt.s328575
• 发表时间: 2022
• 期刊: Psoriasis (Auckland, N.Z.)
• 作者: Al-Janabi A;Yiu ZZN
• 通讯作者: Yiu ZZN